Banner Health hosted media briefing on autosomal dominant trial
PHOENIX (June 16, 2022) — Banner Health today hosted a media briefing with a panel of experts from the Alzheimer’s Prevention Initiative Autosomal Dominant Alzheimer’s Disease (or API ADAD) trial.
Speakers in attendance shared context and information of the crucial contributions related to the API ADAD trial initial data results, as previously released.
- Eric M. Reiman, MD, Banner Alzheimer’s Institute executive director
- Pierre N. Tariot, MD, Banner Alzheimer’s Institute director
- Francisco Lopera, research director, Grupo de Neurociencias de Antioquia at the University of Antioquia
- Richard J. Hodes, MD, director of National Institute on Aging (NIA) at the National Institutes of Health (NIH)
- Rachelle Doody, PhD and MD, global head of Neurodegeneration at Roche and Genentech
About Banner Alzheimer’s Institute
Since its inception in 2006, Banner Alzheimer’s Institute (BAI) has sought to find effective Alzheimer’s disease prevention therapies without losing another generation, to establish a new model of dementia care for patients and family caregivers, and to forge new models of collaboration in biomedical research. It has made groundbreaking contributions to the unusually early detection, tracking, diagnosis, and study of Alzheimer’s, and aims to find an effective prevention therapy by 2025. It includes the pioneering Alzheimer’s Prevention Initiative (API), an extensive profile of research studies and clinical trials, comprehensive clinical, family and community service programs, a leading brain imaging research program, and strategic partnerships with numerous public and private research organizations around the world. Learn more at www.BannerAlz.org.
About the Alzheimer’s Prevention Initiative
The Alzheimer’s Prevention Initiative (API) is an international collaborative formed in 2009 to launch a new era of Alzheimer’s prevention research. Led by the Banner Alzheimer’s Institute, the API conducts prevention trials in cognitively healthy people at increased risk for Alzheimer’s disease. API continues to establish brain imaging, fluid biomarker and cognitive endpoints needed to rapidly test promising prevention therapies. It also leads participant recruitment registries to accelerate enrollment into Alzheimer’s-focused studies. API is intended to provide the scientific means, accelerated approval pathway and enrollment resources needed to evaluate the range of promising Alzheimer’s prevention therapies and find ones that work without losing another generation. For more information, go to https://alzheimerspreventioninitiative.com.
About Grupo de Neurociencias de Antioquia
Grupo de Neurociencias de Antioquia (GNA), at the University of Antioquia in Medellín, is ranked as one of the best research organizations in Colombia. For more than three decades, GNA has characterized what is now considered the world’s largest population with early-onset familial Alzheimer’s disease. GNA has also characterized large and paradigmatic populations with other forms of dementia and other neurogenetic disorders.